A new Belgian company has launched with €8.4 million in seed capital to develop therapies for solid tumours by investigating the interactions between perivascular macrophages and the tumour vasculature. Based on discoveries by Peter Carmeliet and Massimiliano Mazzone, the company will select the most promising targets for drug discovery and validate lead programmes for further development towards the clinic.
